Fish Oil Research Today is a free monthly online journal that collates and summarizes the latest research about Fish Oil, including details on omega-3, dosage, health benefits, diet.

Oral Omega n3-PUFA Therapy (Omacor) Has No Impact on Indices of Heart Rate Variability in Stable Post Myocardial Infarction Patients.

Hamaad A, Kaeng Lee W, Lip GY, Macfadyen RJ

University Department of Medicine, and Department of Cardiology, City Hospital, Dudley Road, Birmingham, B18 7QH, England, UK, robert.macfadyen@swbh.nhs.uk.

OBJECTIVE: To determine the effects of n3-PUFA supplementation, in the dose used in the GISSI-Prevenzione study, on indices of heart rate variability (HRV) in patients following myocardial infarction (AMI). MATERIALS AND METHODS: Open label randomised single blind controlled trial. Thirty eight patients post AMI, stable on standard secondary prevention drug therapy were single blind randomised to receive either Omacor 1 g/day (n = 21) or usual care (n = 17). HRV indices (time and frequency-domain) were measured at baseline and following 3 months of treatment. RESULTS: At baseline there were no significant differences in clinical, biochemical or HRV indices between patient groups. After 3 months therapy there were no observed changes in measured HRV indices in either the Omacor supplemented or 'usual care' groups. CONCLUSIONS: Three month supplementation of omega 3 PUFA (Omacor) 1 g/day has no effect on HRV is patients post AMI.

Published 7 November 2006 in Cardiovasc Drugs Ther.
Full-text of this article is available online (may require subscription).

© 2004-2008 Fish Oil Research Today. All Rights Reserved.